Panel to feature Aditee Kambli, Bharat Serums & Vaccines; Dr. Sushant Kumar, ImmunoACT; Satish Makkina, Procell Biologics; Dr. Shuvankar Ballav, Ipca Laboratories; and Dr. Giriraj Acharya, Mumbai Biocluster
The funding will advance its next-generation multi-antigen VLP vaccine candidate towards clinical readiness, with a focus on manufacturability, scalability and affordability
Deal marks a strategic push into next-generation CAR-T therapies, with pipeline programmes targeting non-Hodgkin lymphoma and small cell lung cancer
The two-day event in Mumbai featured 75+ speakers, 30+ panel discussions and 20+ exhibitors, with focus on spanning peptides, complex generics, oligonucleotides, regulatory pathways, artificial intelligence in drug development and more
Parexel's integrated FSP model combines global talent, AI-driven technology, and expertise to let sponsors easily adjust capacity as pipelines shift
The NIH-funded programme is expected to provide the NUZ-001 for patients who are otherwise ineligible for clinical trials access for up to 96 weeks
The acquisition is expected to accelerate GTBL's transition towards a globally integrated CDMO focused on fermentation and biotechnology-based manufacturing
Dengue vaccine expected to become available for eligible children and adults in the first half of 2027, subject to regulatory processes
He brings leadership experience in medical affairs from Dr. Reddy’s, Sanofi and Abbott
Global licensing deal valued at up to $314.8 million, alongside $2.2 million strategic equity investment
Jigani expansion to add biological buffer manufacturing, strengthen local production and regional supply chains
Shilpa Biologicals to retain IP and manufacturing rights, while Saudi Arabia’s SPIMACO Bio will lead commercialization, regulatory execution and market access across the region
With shared experience across oncology, inflammation and autoimmunity, the two companies will be able to contribute complementary scientific approaches within individual development programs
In-house developed and manufactured biosimilar marks company’s entry into immuno-oncology and aims to improve access to checkpoint inhibitor therapy
The formal collaboration with X-Chem will further strengthen Sygnature's ability to incorporate DEL screening into integrated drug discovery programs from August 2026
New module offers 7,000L reactor capacity and supports complex peptide APIs, while second module planning advances with customer requirements
Updated exploratory results from the Phase 3 ADAURA trial showed that Tagrisso reduced the risk of death by 47% compared with placebo in the primary population of patients with Stage II-IIIA disease
The combination brings together approximately 50 scientists across SCD’s Utrecht operations and TATAA Biocenter’s Gothenburg site, serving pharmaceutical, biotechnology and academic customers
The companies said the technology is intended to improve manufacturing productivity while supporting reliable and cost-effective processes as development programmes advance
Subscribe To Our Newsletter & Stay Updated
